OB 756
Alternative Names: OB-756Latest Information Update: 19 Feb 2025
At a glance
- Originator Hangzhou Biosun Pharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action Janus kinase 2 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Polycythaemia vera
- Phase I/II Myelofibrosis
Most Recent Events
- 07 Dec 2024 Phase-I/II clinical trials in Myelofibrosis in China (PO), before December 2024
- 07 Dec 2024 Adverse events and efficacy data from a phase-II trial in Polycythemia Vera presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024),
- 07 Dec 2024 Efficacy and adverse events data from phase-I/II clinical trials in Myelofibrosis in China presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)